177 Vipivotide Tetraxetan

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy.

Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy.

Journal: ACS nano

Published: June 09, 2026

Emerging Role of Radiopharmaceutical Therapy in Oncology: Advances, Challenges, and Future Directions.

Emerging Role of Radiopharmaceutical Therapy in Oncology: Advances, Challenges, and Future Directions.

Journal: JNCI cancer spectrum

Published: May 15, 2026

Characterization of Adverse Drug Effects to Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.

Characterization of Adverse Drug Effects to Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.

Journal: Cancer biotherapy & radiopharmaceuticals

Published: May 08, 2026

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

Journal: PET clinics

Published: May 07, 2026

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (212Pb), actinium-225 (225Ac), and lutetium-177 (177Lu).

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (212Pb), actinium-225 (225Ac), and lutetium-177 (177Lu).

Journal: EJNMMI radiopharmacy and chemistry

Published: April 17, 2026

Development and evaluation of improved in-house procedure for radiolabelling of theranostic agent [177Lu]Lu-PSMA-617.

Development and evaluation of improved in-house procedure for radiolabelling of theranostic agent [177Lu]Lu-PSMA-617.

Journal: EJNMMI radiopharmacy and chemistry

Published: April 07, 2026

Prostate Cancer: 177Lu-PSMA (Pluvicto).

Prostate Cancer: 177Lu-PSMA (Pluvicto).

Journal: Journal of nuclear medicine technology

Published: March 09, 2026

A 340B View of Pluvicto (lutetium Lu 177 vipivotide tetetan): Financial Misalignment in Radioligand Therapy.

A 340B View of Pluvicto (lutetium Lu 177 vipivotide tetetan): Financial Misalignment in Radioligand Therapy.

Journal: Practical radiation oncology

Published: February 14, 2026

177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.

177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.

Journal: Nuklearmedizin. Nuclear medicine

Published: January 29, 2026

Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.

Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.

Journal: Journal of clinical medicine

Published: December 15, 2025

Development of Prostate Cancer Intramuscular Metastasis During 177Lu-PSMA-617 Treatment.

Development of Prostate Cancer Intramuscular Metastasis During 177Lu-PSMA-617 Treatment.

Journal: Clinical nuclear medicine

Published: December 11, 2025

Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution.

Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution.

Journal: ChemMedChem

Published: December 09, 2025

Showing 1-12 of 79

Last Updated: 06/30/2026